Interestingly, in mice that prophylactically received anti-PD-1 therapy along with CD-HFD, CD4 T cell immunodepletion reduced the tumor burden per liver and decreased the size of tumor nodules, suggesting CD4 T cell control tumor size. This evidence concerns the gene PDCD1 and neoplasm.